Please assess the completion status of the following clinical trial:

Trial Title: IGIV Study for Chronic ITP Patients Ages 3-70

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of chronic ITP~* Platelet count ≤ 20 x 10\^9/L~* When administered corticosteroids at any time within 3 weeks before screening visit, the subject must have completed at least 3 weeks (21 days) of therapy at a stable and constant dose and schedule prior to screening visit~* When administered azathioprine (immunosuppressant) at any time within 3 months before screening visit, the subject must have received a stable dose and schedule for at least 3 months prior to screening visit~* When administered vinca alkaloids (eg., vincristine) at any time within 2 weeks before screening visit, the subject must have received a stable dose and schedule for at least 2 weeks prior to screening visit~* When administered attenuated androgens (eg, danazol) at any time within 8 weeks before screening visit, the subject must have received a stable dose and schedule for at least 8 weeks prior to screening visit.~* Females of childbearing potential must test negative for pregnancy~Key Exclusion Criteria:~* History or clinical evidence of medical conditions (other than ITP) felt to be the underlying cause of the thrombocytopenia~* Diagnosis of secondary immune thrombocytopenia~* History of severe (eg, anaphylactic) reactions to blood or any blood- derived product~* History of intolerance to any component of the IP, such as sorbitol~* Suffering serious and/or life-threatening hemorrhage/bleeding defined as:~* Any intracranial or central nervous system bleeding~* Any hemorrhagic event in which the subject is at risk of death at the time of the event~* Females who are pregnant or nursing an infant child~* Known to have immunoglobulin A (IgA) deficiency~* Known to abuse alcohol, opiates, psychotropic agents or other chemicals or drugs, or has done so within 12 months of the screening visit~* Documented diagnosis of thrombotic complications to polyclonal IVIG therapy in the past~* Unstable or uncontrolled disease, or condition, related to, or impacting, cardiac function: unstable angina, congestive heart failure, uncontrolled arterial hypertension~* Is anemic (hemoglobin \< 9 g/dL)~* Renal impairment (ie, serum creatinine \> 1.5 x upper limit of normal \[ULN\])~* Aspartate aminotransferase or alanine aminotransferase levels \> 2.5 x ULN~* Known to have a positive test for either HCV or HIV (HIV 1/2)~* Splenectomy within the prior 8 weeks to the screening visit~* currently receiving any treatment for ITP except corticosteroids, azathioprine, vinca alkaloids or danazol~* Received an immune serum globulin (ISG) product within the prior 3 weeks (21 days) to the screening visit~* Received any alkylating agent (eg, cyclophosphamide) within 5 weeks prior to the screening visit~* Received rituximab within the prior 3 months to the screening visit~* Was currently receiving, or received, any therapeutic drug or device that was not approved by a Regulatory Authority (US or Canadian) for any indication within the prior 12 weeks to the screening visit

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IGIV3I Grifols 10% (All Subjects) (Type: EXPERIMENTAL): All subjects with Chronic ITP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete